Methylation of CpG islands and associated gene silencing may lead to malignant progression, but the mechanisms of CpG island methylation in cancer are unknown. The tazarotene-induced gene 1 (TIG1), also known as retinoid acid (RA) receptor-responsive 1 gene was first identified as an RA-responsive gene and was shown to be downregulated in prostate cancer. Here, we show that this downregulation is caused by the methylation of the promoter and CpG island of TIG1. TIG1 was methylated in 26 of 50 (52%) primary prostate cancers, but was not methylated in normal tissues or benign hyperplasias. Three of four tumors that metastasized, five of six that were poorly differentiated and all that were assigned a Gleason score higher than 8 (7/7) were methylated in the promoter of TIG1. The samples with peripheral invasion were more frequently methylated (21/32, 66%) than tissues without peripheral invasion (5/18, 28%). In addition, Gleason 7-10 cancers (21/30, 70%) were significantly more frequently methylated compared with Gleason 4-6 cancers (4/18, 22%) (Po0.01). The retinoic acid receptor beta (RAR-beta) gene was frequently methylated as well (42/50, 84%). When TIG1 showed methylation, RAR-beta was also methylated (25/26 samples). In almost all samples where RAR-beta was not methylated, TIG1 was also in an unmethylated state (14/15 samples). The methylation of TIG1 and RAR-beta was positively correlated (r ¼ 0.35; P ¼ 0.017). It is possible that the methylation of the retinoid response gene TIG1 occurred in response to the methylation and inactivation of RAR-beta. These observations may contribute to our understanding of mechanistic events leading to CpG island methylation in cancer.
Introduction
Prostate cancer is the most frequently diagnosed, internal male cancer and the second leading cause of male cancer-related death in the United States and in Europe (Howe et al., 2001) . It is one of the least understood malignant diseases. The molecular mechanisms involved in the malignant progression of prostate cancer include multiple, sequential genetic and epigenetic events.
In the last 10 years, the genetic basis of prostate cancer has been extensively studied. Based on linkage analysis and case control studies, at least six prostate cancer susceptibility loci have been reported for hereditary prostate cancer (Ostrander and Stanford, 2000; Nwosu et al., 2001) . Generally, changes that either activate oncogenes or inactivate tumor suppressor genes can lead to the development and progression of cancer. Several genes have been implicated in the tumorigenesis of prostate cancer including c-myc, c-ErbB2/neu, TP53, APC, GSTP1, PTEN, CD44 and several nuclear hormone receptor genes (Ozen and Pathak, 2000; Elo and Visakorpi, 2001) . Epigenetic inactivation of tumor suppressor genes through DNA methylation in CpGrich promoter regions contributes to tumorigenesis (Baylin and Herman, 2000; Jones and Baylin, 2002) . In prostate cancer, aberrant methylation is involved in the inactivation of various important genes such as E-cadherin, CD44, RASSF1A, GSTP1, the endothelin B receptor, p16, the androgen receptor gene, the retinoic acid receptor beta (RARbeta), the estrogen receptor beta (ER-beta) and the caveolin-1 gene (Lee et al., 1994; Nelson et al., 1997; Cui et al., 2001; Kito et al., 2001; Li et al., 2000 Li et al., , 2001 Nakayama et al., 2001; Pao et al., 2001; Kuzmin et al., 2002; Liu et al., 2002) . When tested, loss of the expression of these genes was associated with CpG island hypermethylation, and expression could be restored after treatment with 5-aza-2 0 -deoxycytidine (5-Aza-CdR), a DNA methyltransferase inhibitor.
Retinoid acid (RA) and its synthetic analogs exert their biological affects through two families of nuclear receptors: RA receptors (RAR a, b, g ) and retinoid X receptors (RXR a, b, g), which are ligand-dependent transcription factors of the steroid/thyroid hormone nuclear receptor superfamily (Chambon, 1994; Boehm et al., 1995) . Activated RARs bind to retinoic acidresponsive elements (RAREs) in the promotors of genes & 2004 Nature Publishing Group All rights reserved 0950-9232/04 $25.00 www.nature.com/onc ONCOGENOMICS and thus regulate gene expression (Evans, 1988; Mangelsdorf et al., 1993) . Retinoids are essential for normal prostate function (Howell et al., 1967; Wolbach and Howe, 1978; De Luca, 1991) and exhibit antiproliferative and preventive efficacy in experimental prostate carcinoma (Pollard et al., 1991; Pienta et al., 1993; Stearns et al., 1993) . It has been demonstrated that prostate epithelial cells exhibit a squamous metaplastic phenotype during vitamin A deficiency, and prostate cell carcinogenesis could be prevented by retinoic acid and its analogs. These findings suggest that retinoiddependent cellular events are involved in the prevention of tumorigenic transformation of prostate epithelial cells. RARs and RXRs are nuclear transcription factors that mediate the action of retinoids. RAR-beta is decreased or downregulated in a number of tumors including lung, breast and head and neck cancers. (Picard et al., 1999; Qiu et al., 1999; Lotan, 2002) . The RAR-beta promoter region is frequently methylated in prostate cancer samples .
Among a number of retinoid-induced genes in various systems, the tazarotene-induced gene 1 (TIG1), also known as RAR-responsive 1 gene, was first identified as a novel RAR-responsive gene in skin (Nagpal et al., 1996) . TIG1 is induced in an RAR-specific manner in a variety of human skin-related systems. TIG1 cDNA contains an open-reading frame coding for a putative protein of 228 amino acids. It appears to be a transmembrane protein and contains a putative hyaluronic acid-binding motif. TIG1 might function as a cell adhesion molecule whose expression on the cell surface might lead to better cell-cell contact and reduced proliferation (Jing et al., 2002) . Thus, it is important to consider the potential function of TIG1 and its role in RAR-mediated biology. In previous work, TIG1 has been identified as a potential tumor suppressor gene for human prostate cancer (Jing et al., 2002) . It was demonstrated that the decreased expression of TIG1 was associated with an increase in the malignant potential of prostate carcinoma cells. The restoration of TIG1 expression in the highly malignant PC-3M cells, which do not express TIG1 mRNA, greatly reduced their invasiveness in vitro and their tumorigenicity in nude mice (Jing et al., 2002) .
In the present study, we have investigated the methylation status of the TIG1 gene in primary prostate cancer samples and analysed the expression of TIG1 in tissues and prostate cancer cell lines to explore the candidacy of TIG1 as a tumor suppressor gene in prostate carcinoma. We also determined the relationship between the methylation of the RAR-beta gene and methylation of the TIG1 gene.
Results

Hypermethylation of CpG sequences in the TIG1
promoter region in primary human prostate cancers TIG1 is considered to be a putative tumor suppressor gene whose diminished expression may be involved in malignant progression of prostate cancer (Jing et al., 2002; Lotan, 2002) . The decreased expression of TIG1 was found to be associated with an increase in the malignant characteristics of both prostate cell lines and tissues. To explore the candidacy of TIG1 as a tumor suppressor gene in prostate cancer, we treated genomic DNA with sodium bisulfite followed by MSP to analyse the methylation status of the TIG1 CpG island (Figure 1 ) in 50 primary prostate cancer samples and two benign prostate hyperplasia tissues. In MSP analysis (Figure 2) , 52% of the primary prostate cancer samples (26/50) showed the methylation of the promoter CpG island. Interestingly, the frequency of methylation was higher in advanced tumors compared with early-stage tumors (Table 1) . We included two benign hyperplasia samples in this study, neither of them showed methylation. However, three of four tumors that metastasized (75%), five of six that were poorly differentiated (83%) and all that were assigned a Gleason score higher than 8 (7/7, 100%) were methylated in the promoter of TIG1. Samples with peripheral invasion were more frequently methylated (21/32, 66%) than tissues without peripheral invasion (5/18, 28%) (Po0.01; w 2 test). In addition, Gleason 7-10 cancers (21/30, 70%) were significantly more frequently methylated compared with Gleason 4-6 cancers (4/18, 22%) (Po0.01; w 2 test). Owing to the size of our sample, our data did not meet the statistical criteria for significance for other pathoclinical parameters. We also analysed eight matching normal prostate tissues in parallel (Figure 3 ). None of them was methylated. To confirm that the methylation status results obtained with the MSP assay are not limited to the few CpG sites tested by MSP, we used bisulfite sequencing of genomic DNA to determine the methylation status of other CpG dinucleotides of the TIG1 CpG island (Figure 4 ). We analysed 18 CpGs in a 195 bp fragment that is located in the promoter region upstream of the ATG codon. We tested 12 tissues: four tumor samples (T1, T3, T6, T57) that showed methylation by MSP; four tumor samples (T21, T25, T37, T38) that showed no methylation by MSP and four normal tissues (N21, N49, N57, N59) that showed no methylation by MSP. The sequencing results ( Figure 4) were consistent with the MSP results, indicating that methylation affects many CpG sites in the TIG1 CpG island and that the MSP results are generally representative of the TIG1 methylation status.
We also analysed the methylation status of CpGs near the putative RA-responsive element that is located 5 0 to the TIG1 promoter CpG island (see Figure 1 ). We sequenced 10 CpGs in a 213 bp fragment of four tumor samples (T1, T3, T6, T57) and four normal tissues (N47, N53, N57, N61). All of the samples, even the normal tissues, showed almost complete methylation of these sequences (data not shown), indicating that the methylation-free status is not maintained outside of the CpG island.
TIG1 expression in prostate cancer and re-expression with a DNA-demethylating agent
We performed RT-PCR analysis on several tumor and normal tissue pairs to determine the expression levels of Figure 2 Methylation analysis of TIG1 in primary human prostate cancers. Bisulfite modified genomic DNA extracted from primary human prostate tumors was amplified with methylated DNA-specific primers (M) or with unmethylated DNA-specific primers (U). The PCR products were separated on 2% TBE agarose gels and visualized by ethidium bromide staining Figure 3 Methylation analysis of TIG1 in primary human prostate tumors and in matching normal tissues. The methylation-specific PCR analysis of TIG1 in primary human prostate tumors (T) and matching normal tissues (N) was conducted with methylated DNAspecific primers (M) or with unmethylated DNA-specific primers (U) TIG1 and RAR-beta in prostate cancer J Zhang et al TIG1. We were able to obtain good-quality RNA from three matched normal samples and prostate carcinomas. In these samples, the tumor DNA was methylated, while the normal DNA was not. We show by semiquantitive RT-PCR that the expression of TIG1 is very low in the tumor tissues (which had not been microdissected, and hence the low signal may come from normal cell contamination) but TIG1 mRNA is present in the normal matching tissue ( Figure 5 ). Strongly reduced expression was seen in samples that have partially unmethylated DNA. This could be due to mosaic methylation patterns, not detectable by the MSP assay, or, more likely, could be due to mechanisms other than the methylation of the promoter sequence of TIG1, for example, the lack of transactivating factors. The epigenetic inactivation of genes can be reversed by the treatment of cells with the DNA methylation inhibitor 5-Aza-CdR. LNCaP and PC-3, prostate cancer cell lines that do not express TIG1 at a significant level, were treated with this compound. To evaluate the expression of TIG1 in those cells, we performed semiquantitative RT-PCR. Our results show that transcripts of TIG1 were very low in LNCaP cells and were undetectable in PC-3 cells. 5-Aza-CdR reactivated the expression of TIG1 in both LNCaP and PC-3 cell lines (Figure 6 ), indicating that repression is at least in part mediated by DNA methylation.
Methylation analysis of the RAR-beta promoter region
We also examined the methylation status of the P2 promoter of the RAR-beta gene in the 50 primary prostate cancer samples, two prostate hyperplasia tissues and eight normal tissues (Table 2) . RAR-beta was methylated in none of the two benign hyperplasia tissues, while it was commonly methylated in the cancer samples (42/50, 84%). Three of eight matching normal tissues showed the methylation of RAR-beta. As their cancerous counterparts also showed methylation, this might be due to tumor cell infiltration or alternatively, the methylation of RAR-beta in normal tissue could be a tumor predisposing event. There was no obvious relationship between the methylation of RAR-beta and tumor grade except that tumors with a Gleason score of greater than 8 were all methylated (7/7). Most importantly, our results point to a correlation between the methylation status of TIG1 and RAR-beta. When TIG1 showed methylation, RAR-beta was also methylated (25/26 samples; only one sample was an exception). In almost all tissue samples where RAR-beta was not methylated, TIG1 was in an unmethylated state (14/15, samples). The methylation of TIG1 and methylation of RAR-beta in prostate cancer tissues were positively correlated (r ¼ 0.34, P ¼ 0.017; regression analysis). It is possible that the methylation of the TIG1 gene occurred in response to the methylation and inactivation of RAR-beta.
Methylation analysis of the ER-beta and RASSF1A promoter regions
The correlation between TIG1 methylation and RARbeta methylation could, at least in part, be a consequence of a hypothetical CpG island methylator phenotype (Toyota et al., 1999) found perhaps in a Methylation data were obtained from five clones of each sample. White and black squares represent completely unmethylated or completely methylated CpGs, respectively (i.e. five out of five clones). Gray squares represent partially methylated CpGs (i.e. of the five sequenced clones, between one and four were methylated at each site analysed). In total, 18 CpGs were tested; their numbers are shown on the top Figure 5 Expression of TIG1 in prostate cancer samples and matching normal tissues. TIG1 and GAPDH were analysed by RT-PCR using PCR cycle numbers chosen to give product amplification in the exponential range. N, normal tissue; T, tumor. Matching samples are indicated by straight lines TIG1 and RAR-beta in prostate cancer J Zhang et al subset of prostate carcinomas. This possibility led us to investigate the methylation of two additional genes in the 50 prostate cancer samples (Table 2) . Data for RASSF1A methylation were obtained from previous work (Liu et al., 2002) . The methylation of RAR-beta and RASSF1A was not statistically correlated, although there was a trend for an association (r ¼ 0.26, P ¼ 0.069). The ER-beta gene was highly methylated in our collection of prostate cancer samples confirming the previous findings (Lau et al., 2000; Li et al., 2000) . Overall, 44 of 50 (88%) samples were methylated ( Table 2 ). The methylation of ER-beta was detected in four of eight normal tissues as well. The methylation of ER-beta and RAR-beta was not statistically correlated (r ¼ 0.14, P ¼ 0.337).
Discussion
Although the function of TIG1 is not completely understood, TIG1 was localized to the short arm of chromosome 3, between 3p13 and 3p12 (Jing et al., 2002) . It has been suggested that the short arm of chromosome 3 harbors several tumor suppressor genes and it exhibits loss of heterozygosity in many types of human cancer (Maestro et al., 1993; Hosoe et al., 1994; Wei et al., 1996; Kok et al., 1997; Uzawa et al., 1998) , although 3p losses have been reported more rarely in prostate cancers. TIG1 may be a candidate tumor suppressor gene that is frequently incapacitated in malignant prostate carcinoma cells. In our study, we demonstrated aberrant methylation of the TIG1 gene in a high percentage of clinical prostate cancer samples. We found that promoter hypermethylation of TIG1 was present in 52% (26/50) of primary prostate cancers but not in normal or benign hyperplasia tissues. To demonstrate that promoter methylation is causing gene silencing, a demethylation study was carried out. Treatment with the DNA methylation inhibitor 5-Aza-CdR restored the expression of TIG1 in LNCaP and PC-3 cells. This result suggests that the reduced expression of TIG1 is related to gene promoter methylation. It has been reported that TIG1 expression was absent in virtually all prostate cancer samples analysed by in situ hybridization (Jing et al., 2002) . The expression of TIG1 mRNA in tumor cells was difficult to assess in our study due to the presence of normal cells in the tumor cell population and because of limitations in RNA quality. Available sample pairs showed a reduction of TIG1 mRNA in tumor tissue ( Figure 5 ). We hypothesize that the lack of TIG1 expression may be a consequence of promoter methylation and/or absence of RAR-beta transactivation of TIG1 due to the very common methylation silencing of the RAR-beta gene ( Table 2 ). The methylation of TIG1 was low in low-grade tumors and increased as the Gleason score increased. We conclude that TIG1 may be a gene whose diminished expression contributes to the malignant progression of prostate cancer. The hypermethylation of the TIG1 gene may be a late event during malignant progression. Although the general understanding that retinoids are gene regulatory molecules has prevailed for a long time 
M, moderate; P, poor; ND, not determined. c U, only unmethylated alleles detected by MSP; M, only methylated alleles were detected; M/U, methylated and unmethylated alleles were present since the discovery of the retinoic acid nuclear receptors, TIG1 is the first gene to be identified specifically because of its RAR-beta agonist responsiveness (Nagpal et al., 1996) . The tumor suppressing activity of TIG1 may be related to its ability to react to retinoid stimulation. Retinoids can exert potent growth inhibitory and cell differentiation activities by binding to specific nuclear receptors. In earlier studies, TIG1 was found to be induced in a retinoid-specific manner in a variety of human skin-related systems (Nagpal et al., 1996) .
It can be assumed that the methylation of CpG sequences in the TIG1 promoter is critical for the silencing of the gene by blocking access of cis-acting transcription factors to their binding sequences. This could be a direct inhibition of binding by methylation, or more likely, could occur through the establishment of a repressed chromatin structure at the methylated CpG island (Bird and Wolffe, 1999; Ng and Bird, 1999) . The RARE sequences located 5 0 of the TIG1 CpG island were methylated in all normal and cancer tissues tested. It is possible, however, that RAR receptor complexes can bind to these DNA sequences regardless of methylation, since CpGs were not embedded directly within the core recognition sequences.
Our data also confirm that promoter hypermethylation of the RAR-beta gene occurs frequently in prostate cancer tissues. It is interesting that the methylation status of TIG1 and RAR-beta are statistically correlated (P ¼ 0.017). When TIG1 was methylated in any prostate cancer tissue, RAR-beta would almost definitely show methylation (25/26 cases). This is consistent with the finding that TIG1 is induced in an RAR-specific manner. It is possible that liganded RAR-beta may bind to targeted TIG1 cis-elements inducing and maintaining TIG1 expression and blocking the access of the DNA methylation machinery to the TIG1 CpG island. The loss of RAR-beta-mediated transactivation could diminish the protective effect of the promoterbound transcription factor and RNA polymerase II complexes, which would then allow methylation to spread into the TIG1 promoter area. In fact, it has been shown that active transcription and promoter-bound transcription factors can prevent the methylation of CpG island sequences (Pfeifer et al., 1990; Brandeis et al., 1994; Macleod et al., 1994) . The TIG1 CpG island is flanked on both sides by several putative retinoic acid response element sequences (Figure 1 ). It will be important to determine if these elements are functional in the activation of TIG1 by retinoids. The RAR-beta promoter is under the control of a high-affinity retinoic acid response element itself. Thus, once silencing of RAR-beta has occurred, the lack of RAR-beta may reinforce the inactive silent state at its own promoter probably promoting methylation as a secondary repression mechanism. A recent report indicated that the methylation of RAR-beta and the cellular retinalbinding protein 1 (CRBP1) occurred frequently in the same tumors . CRBP1 also is inducible by retinoids (Wei et al., 1989; Fisher et al., 1995) and a similar mechanisms of coordinated methylation silencing of RAR-beta and one of its target genes may be operative.
It is proposed that RAR-beta silencing by promoter methylation is a crucial event in prostate tumor progression, and that epigenetic changes in the TIG1 promoter, and possibly in the promotors of other retinoid response genes, are downstream events to RAR-beta deficiency. Then, in the case of TIG1, silencing will affect cell-cell contacts and result in an increased proliferation and invasiveness of tumor cells.
Materials and methods
Cell line and tissues
The human prostate cancer cell lines LNCaP and PC-3 were generous gifts from Dr S Chen (City of Hope) and were cultured in the recommended medium. All nonmicrodissected primary frozen prostate carcinoma tissues, prostate hyperplasia samples and matching adjacent normal tissues were histopathologically classified and obtained from the Anatomic Pathology Department of the City of Hope National Medical Center with approval from the Institutional Review Board with respect to human subjects and minority inclusion (Duarte, CA, USA).
Methylation analysis
DNA was isolated from frozen tissues by digestion with proteinase K (0.5 mg/ml) as described by Dammann et al. (2000) . The methylation status of the TIG1 promoter region was determined by a bisulfite modification protocol (Clark et al., 1994; Dammann et al., 2000) . Briefly, genomic DNA (1 mg) was denatured in NaOH (0.3 M) for 15 min at 371C. Cytosines were sulfonated in sodium bisulfite (3.26 M; Sigma) in the presence of hydroquinone (5 mM; Sigma) in a water bath for 16-18 h at 561C. Then the DNA samples were desalted through columns using the Wizard DNA clean-up system (Promega) and desulfonated in NaOH (0.3 M) at 371C for 15 min. The treated DNA samples were precipitated with ethanol and resuspended in 10 mM Tris-Cl, pH 7.8, 1 mM EDTA. The modified DNA was subjected to methylationspecific PCR (MSP). Two sets of primers were used to amplify methylated or unmethylated DNA sequences specifically, respectively, obtained after sodium bisulfite treatment. To analyse the TIG1 methylation status, 100 ng of bisulfite-treated genomic DNA was amplified with methylation-specific primers, TIG1MU (5 0 -GCGGGGTTCGGGGATTTC-3 0 ) and TIG1ML (5 0 -GTACGCGAAC-AAACAAACG-3 0 ) or unmethylation-specific primers TIG1UU (5 0 -GTGGGGTT TGGGGA-TTTTGAT-3 0 ) and TIG1UL (5 0 -ATACACAAA CAAA-CAAACACA-3 0 ) in a 100 ml reaction volume containing 200 mM of each dNTP and Hotstar Taq polymerase (Qiagen). PCR was performed with an initial incubation at 951C for 15 min and then 40 cycles of 941C for 30 s, specific annealing temperature (561C for TIG1MU/TIG1ML, 551C for TIG1UU/TIG1UL) for 50 s and 721C for 50 s, followed by a final extension step at 721C for 10 min. PCR products (10 ml) were loaded onto 2% TBE agarose gels, which were then stained with ethidium bromide and visualized under UV illumination. The same method was used to analyse the RAR-beta promoter P2 methylation status. The primers were methylation-specific primers URAR-b-M (5 0 -TT GAGGATTGGGATGTCGAGAACGC-3 0 ) and LRARbeta-M (5 0 -CTTACTCGACCAATCCAACCGAACG-3 0 ) or unmethylation-specific primers URAR-beta-U (5 0 -TTGAG GATT-GGGATGTTGAGAATGT-3 0 ) and LRAR-beta-U (5 0 -CTTACTCAACCAAT-CCAACCAAAACA-3 0 ). The specific annealing temperatures for RAR-beta were 561C for the unmethylation-specific primers and 581C for the methylationspecific primers. For the analysis of the methylation of the ER-beta gene, methylation-specific primers UER-beta-M (5 0 -GCGTTGGGCGTTTTTGAGATCGTC-3 0 ) and LERbeta-M (5 0 -CAATTATTTCTCGCAACCTCCGCG-3 0 ) or unmethylation-specific primers UER-beta-U (5 0 -GTGTTGGG TGTTTTTGAGATTGTT-3 0 ) and LER-beta-U (5 0 -ACAAT TATTTCTCACAACCTCCACA-3 0 ) were used. The analysis of methylation in the RASSF1A CpG island was carried out by MSP as described previously (Liu et al., 2002) . For bisulfite sequencing, 100 ng of bisulfite-treated genomic DNA was amplified with TIG1 sequencing primers: TIG1seqU (5 0 -AGG AGTGGTTTTATGGGGAT-3 0 ) and TIG1seqL1 (5 0 -AACC CGAACCAAAAAA-CAAACA-3 0 ), or with the putative RARE sequencing primers: RareU (5 0 -GTTATTTGTT TAAAAA-GAGTTG-3 0 ) and RareL (5 0 -CAAACAATTC TA-CCTCAACCTC-3 0 ) in the reaction buffer (100 ml) containing dNTPs and Hotstar Taq polymerase at 951C for 15 min and then 40 cycles of 941C for 30 s, 581C (531C for RARE sequencing) for 50 s and 721C for 50 s, followed by a final extension step at 721C for 10 min. The PCR products were purified using QIAquick PCR purification kits (Qiagen) and then ligated into the pCR2.1 vector (Invitrogen). Five clones of each sample were sequenced for confirmation.
Expression of TIG1
The prostate cancer cell lines LNCaP and PC-3 were treated with an inhibitor of DNA methylation, 5-Aza-CdR (Sigma).
Cells (2 Â 10 6 cells per plate) were grown for 4 days in the presence of different concentrations of 5-Aza-CdR (1, 2 or 5 mM). RNA was isolated and RT-PCR was performed to analyse the TIG1 transcript. Total cellular RNA was isolated using the TriZOL reagent (Life Technologies). RNA (1.5 mg) was preassociated with 25 pmol of a lower primer TIG1RTL (5 0 -CTCTGGGTTGTAGCGCTCTGTG-3 0 ) from exon 2 of the TIG1 gene. After the RT reaction, 5 ml was added to the PCR reaction mix containing Hotstar PCR master mix, 50 pmol upper primer TIG1RTU (5 0 -CGCTTCACTTCTTC AACTTCC-3 0 ) from TIG1 gene exon 1 and 50 pmol lower primer TIG1RTL described above. The PCR conditions were 951C for 15 min and then 25 cycles of 951C for 30 s, 551C for 50 s and 721C for 50 s, followed by a final extension of 721C for 10 min. PCR products were separated on a 2% TBE agarose gel and stained with ethidium bromide, or transferred to a nylon membrane, then hybridized with a labeled probe and visualized by autoradiography. The expression of GAPDH was analysed as a control (Liu et al., 2002) .
Abbreviations TIG1, tazarotene-induced gene 1; RAR-beta, retinoic acid receptor beta; ER-beta, estrogen receptor beta; RASSF1A, Ras association domain family 1A gene; MSP, methylationspecific PCR.
